Meet the Team...
Our success at Taran Therapeutics is a reflection of the hard work and commitment of our skilled team. We believe in harnessing diverse expertise to develop groundbreaking medical solutions. Get to know the professionals whose passion fuels our mission to enhance patient care and treatment outcomes.
Cameron Durrant
MD, DRCOG, MRCGP, MBA, FLSW
Founder, Chariman & CEO
Dr. Durrant has spent a lifetime as a physician and as a leader in the development, commercialization, and access to important medicines addressing serious conditions.
As the founder of Taran Therapeutics, he brings experience as a big pharmaceuticals company senior leader at some of the most successful global companies, extensive end-to-end product development, launch and commercialization expertise, including 5 global blockbusters, a small company/biotech entrepreneur, operating executive and as a seasoned Chief Executive Officer and board member of both public and private companies.
Dr. Durrant was Chairman of the Board and CEO of Humanigen for eight years before acquiring Humanigen's assets on behalf of Taran early in 2024.
Dr. Durrant serves on the boards of several healthcare companies. He has been a senior executive at Johnson and Johnson, Pharmacia, GSK and Merck.
Dr. Durrant earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia, and his MBA from Henley Management College, Oxford, UK. He was Elected as a Fellow of the Learned Society of Wales in 2023 and is a Professor at the Cardiff University School of Medicine.
He has authored or co-authored multiple scientific publications which have appeared in prestigious peer-reviewed medical journals and is the inventor or co-inventor of many dozens of patents.
Michael Schuster
BS, MS, MBA
Board Member
Michael Schuster Co-Founded Mesoblast Limited and Angioblast Systems Inc. in 2004. He was part of the executive management team at both companies and currently serves as the head of pharma partnering and project management at Mesoblast Limited and was previously the head of the company's investor relations outreach program.
Mr Schuster was Executive Vice President of Global Therapeutic Programs from 2010 to 2013 and was the Director of Business Development and Vice President of Operations from 2004 to 2010.
He holds an undergraduate degree in science from Tufts University, a Master's degree in Immunology & Microbiology from New York Medical College, and an MBA from Fordham University in New York.